The researchers found that when the HCQ–AZM combination was given at lower dosages to treat ventilated COVID-19 patients, the risk of death was more than three times higher.
“We found that when the cumulative doses of two drugs, HCQ and AZM, were above a certain level, patients had a survival rate 2.9 times the other patients,” the authors of the study noted.
What
>The researchers found that when the HCQ–AZM combination was given at lower dosages to treat ventilated COVID-19 patients, **the risk of death was more than three times higher**.
>“We found that when the cumulative doses of two drugs, HCQ and AZM, were above a certain level, patients had a **survival rate 2.9 times the other patients**,” the authors of the study noted.
What
(post is archived)